On April 1, 2026, the FDA approved Foundayo (orforglipron) from Eli Lilly, marking the first oral GLP-1 receptor agonist approved specifically for chronic weight management. This is a genuinely significant moment in obesity medicine. For the millions of people who have avoided injectable GLP-1 drugs like Wegovy and Zepbound due to needle aversion, cost, or supply shortages, Foundayo represents a new and more accessible path forward.
How Foundayo Works
Foundayo belongs to the GLP-1 receptor agonist class, the same family as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). It mimics the naturally occurring hormone GLP-1, which is released by the gut after eating. GLP-1 slows gastric emptying, reduces appetite signals in the brain, and improves insulin sensitivity. The key difference is that orforglipron is a small molecule rather than a peptide, which means it can survive the digestive process and be absorbed as a pill. No injection required.
The standard dosing protocol starts at 3 mg daily for the first two weeks, then increases to 6 mg for two weeks, 12 mg for two weeks, 24 mg for two weeks, and finally reaches the maintenance dose of 36 mg or 48 mg daily, depending on tolerability and response. Unlike oral semaglutide (Rybelsus), Foundayo does not require fasting before or after taking it. You can take it with food at any time of day.
Efficacy: What the Clinical Data Shows
The ATTAIN phase 3 trials enrolled over 3,900 adults with obesity or overweight with at least one weight-related comorbidity. At the 48 mg dose over 72 weeks, participants achieved an average weight loss of 12.4% of body weight compared to 2.1% with placebo. Approximately 52% of participants lost at least 10% of their body weight, and 27% lost at least 15%.
For context, injectable semaglutide (Wegovy) achieves roughly 15-17% weight loss in trials, and tirzepatide (Zepbound) achieves 18-22%. So Foundayo is somewhat less potent than the injectable options, but the convenience of a daily pill with no dietary restrictions represents a meaningful trade-off that many patients will prefer.
Pricing and How to Get It
Eli Lilly has priced Foundayo at $149 per month for self-pay patients through LillyDirect, its direct-to-consumer pharmacy platform. This is dramatically lower than the list prices for Wegovy ($1,349/month) and Zepbound ($1,059/month). For patients with commercial insurance, Lilly is offering a savings card that brings the out-of-pocket cost down to $25 per month.
Starting July 1, 2026, Medicare Part D will cover Foundayo under the Bridge Program at a $50 monthly copay cap. This is particularly significant for seniors, who represent one of the fastest-growing demographics seeking GLP-1 treatment.
LillyDirect began shipping Foundayo on April 6, 2026. Retail pharmacy availability is expected to ramp up over the following weeks, though initial supply may be limited at some locations. For independent provider comparisons and safety monitoring, visit GLP-1 Watchdog.
Side Effects
The most common side effects in clinical trials were gastrointestinal. Nausea occurred in 28% of participants (compared to 8% with placebo), diarrhea in 18%, vomiting in 10%, and constipation in 9%. Most GI side effects were mild to moderate and occurred during the dose escalation phase, improving once participants reached their maintenance dose.
Serious adverse events were uncommon. There were no cases of pancreatitis in the treatment group, and rates of gallbladder events were low and comparable to placebo. Liver enzyme elevations were observed in a small number of participants but were generally transient. Lilly has committed to a post-marketing surveillance program to track long-term safety data.
Who Is a Good Candidate?
Foundayo is FDA-approved for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol. It is not approved for patients under 18. Women who are pregnant or planning to become pregnant should not take Foundayo, as GLP-1 medications have not been studied in pregnancy.
Patients who have tried injectable GLP-1 drugs and could not tolerate the side effects may find that Foundayo is better tolerated due to its different pharmacokinetic profile. Conversely, patients who need maximum weight loss and are comfortable with injections may still prefer Wegovy or Zepbound for their greater efficacy.
The Bottom Line
Foundayo is not the most potent GLP-1 medication on the market, but it does not need to be. At $149 per month with no injection required and no fasting restrictions, it removes the most common barriers that have kept people from accessing GLP-1 therapy. The 12.4% average weight loss is clinically meaningful and sufficient to improve metabolic health markers for most patients. For many people, this will be the drug that finally makes GLP-1 treatment practical and affordable.